EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Engineering Bone‐Targeted LNP Delivery of Anti‐Sclerostin Antibody mRNA for the Treatment of Osteoporosis

Pengcheng Ren iD, Diaodiao Wang, Wenqiang Sun, Danning Li, Sidong Yang iD, Shudong Zhang, Yiquan Zhang, Yubo Liu, Peng Hu, Jiaxin Li, Qi Yao iD

Journal of Biomedical Materials Research Part A · 2026-07 · 114 (7)

DOI: 10.1002/jbm.a.70103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biomedical Materials Research Part A, online erschienen am 23.06.2026. Verfasst von Pengcheng Ren und 10 weiteren Autor:innen. Beteiligte Einrichtung: Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Osteoporosis, RNA, Messenger, Antibodies, Bone and Bones. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Natural Science Foundation, the National Natural Science Foundation of China, the Public Welfare Key Special Project for the Veterinary Drug In-dustry, China Institute of Veterinary Drug Control.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Messenger RNA (mRNA) therapy represents a transformative platform in regenerative medicine, but its application to skeletal disorders remains limited by the pronounced hepatic tropism of conventional lipid nanoparticle (LNP) delivery systems. To redirect the distribution of biomolecules to bone tissue, we developed a bone‐targeting mRNA nanocarrier (SA@LNP‐D) through microfluidic synthesis followed by surface conjugation of the Asp8 peptide (binding to hydroxyapatite). This system enables efficient expression of anti‐sclerostin antibody mRNA in bone tissue, thereby achieving therapeutic effects for osteoporosis treatment. Our in vitro experimental results have demonstrated that LNP modified with bone‐targeting peptides exhibits significant bone affinity and can efficiently bind to hydroxyapatite and isolated bone. Furthermore, the in vivo results confirmed that SA@LNP‐D effectively reduces hepatic sequestration and specifically accumulates in bones through mineral‐directed anchoring. In a murine ovariectomy model of osteoporosis, systemic delivery of bone‐targeted LNP demonstrated a stronger therapeutic effect compared to conventional LNP. It not only stimulated bone formation but also inhibited bone resorption, thereby significantly restoring trabecular bone mass and microstructure. Together, this work establishes a targeted, nonhepatic mRNA delivery strategy that offers a safe and effective therapeutic option for osteoporosis and related skeletal conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteoporosisRNA, MessengerAntibodiesBone and BonesNanoparticlesLipidsAnimalsFemaleMiceDurapatiteHumansOvariectomyLiposomes

Stichwörter der Autor:innen

LNPbone‐affinity peptidemRNAosteoporosissost‐antibody

Substanzen

RNA, MessengerAntibodiesLipidsLipid NanoparticlesDurapatiteLiposomes

Autor:innen und Institutionen

  • Capital Medical University, Beijing, China.
  • Department of Joint Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • State Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering Chinese Academy of Sciences, Chinese Academy of Sciences, Beijing, China.
  • Department of Orthopaedic Surgery, Hebei Medical University Third Hospital, Shijiazhuang, China.
  • Senior Department of Orthopaedics, The Fourth Medical Center of PLA General Hospital, Beijing, China.
  • National Classical Swine Fever Reference Laboratory, China Institute of Veterinary Drug Control, Beijing, China.

ORCID-Profile: Pengcheng Ren, Sidong Yang, Qi Yao

Förderung

  • Beijing Natural Science Foundation
  • the National Natural Science Foundation of China
  • the Public Welfare Key Special Project for the Veterinary Drug In-dustry, China Institute of Veterinary Drug Control
  • Beijing Hospitals Authority's Ascent Plan
  • Laboratory for Clinical Medicine, Capital Medical University
  • the National Key Research and Development Program of China
  • Natural Science Foundation of Beijing Municipality

Zitieren

APA

Ren, P., Wang, D., Sun, W., Li, D., Yang, S., Zhang, S., Zhang, Y., Liu, Y., Hu, P., Li, J., & Yao, Q. (2026). Engineering Bone‐Targeted LNP Delivery of Anti‐Sclerostin Antibody mRNA for the Treatment of Osteoporosis. Journal of Biomedical Materials Research Part A, 114(7). https://doi.org/10.1002/jbm.a.70103

Vancouver

Ren P, Wang D, Sun W, Li D, Yang S, Zhang S, et al. Engineering Bone‐Targeted LNP Delivery of Anti‐Sclerostin Antibody mRNA for the Treatment of Osteoporosis. Journal of Biomedical Materials Research Part A. 2026;114(7). doi:10.1002/jbm.a.70103

BibTeX
@article{Ren2026,
  author = {Ren, Pengcheng and Wang, Diaodiao and Sun, Wenqiang and Li, Danning and Yang, Sidong and Zhang, Shudong and Zhang, Yiquan and Liu, Yubo and Hu, Peng and Li, Jiaxin and Yao, Qi},
  title = {Engineering Bone‐Targeted LNP Delivery of Anti‐Sclerostin Antibody mRNA for the Treatment of Osteoporosis},
  journal = {Journal of Biomedical Materials Research Part A},
  year = {2026},
  volume = {114},
  number = {7},
  doi = {10.1002/jbm.a.70103}
}
Kostenlos starten →